We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Lipocine

News List

Lipocine Announces Update on Jury Trial in Patent Infringement Lawsuit Against Clarus Therapeutics prnewswire
December 30, 2020
Lipocine Inc., a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced that Judge William C. Bryson of the United States District Court of Delaware has postponed the February 8, 2021 jury trial scheduled to ...
Lipocine Receives FDA Clearance for Testing of NASH Candidate americanpharmaceuticalreview
July 25, 2019
Lipocine has received clearance from the U.S. Food and Drug Administration (FDA) to clinically investigate LPCN 1144 in an expanded target population of adult male non-alcoholic steatohepatitis (NASH) patients.
Lipocine Announces Tlando NDA PDUFA Action Date of November 9, 2019 drugs
May 15, 2019
Lipocine Announces Tlando NDA PDUFA Action Date of November 9, 2019.
FDA Panel Rejects Lipocine's Testosterone Pill biospace
January 12, 2018
Lipocine Announces Outcome of FDA Advisory Committee Meeting for TLANDO, Testosterone Replacement Therapy in Adult Males with Hypogonadism